TrialA Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease
Trial details
- Registry ID
- NCT05956626
- Phase
- Phase 2, Phase 3
OCGN
Ocugen
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
2Trials in this database
6Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt DiseaseNCT05956626 | Ocugen | Phase 2, Phase 3 | Active not recruiting | 2026-09-28Estimated |
| A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis PigmentosaNCT06388200 | Ocugen | Phase 3 | Active not recruiting | 2027-02-12Estimated |
A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
Trial details
- Registry ID
- NCT06388200
- Phase
- Phase 3
Latest recorded trial changes
A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease
NCT05956626 · Ocugen
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting
A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
NCT06388200 · Ocugen
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Number of participants with change in functional vision in the study eye of RP subjects as assessed by LDNA
Measure: Number of participants with change in functional vision in the study eye in Gene Agnostic group as assessed by LDNA
+ After
Measure: Change in functional vision from baseline to week 52 in pooled analysis when study eyes in treatment group were compared to study eyes in untreated control
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
150 participants (planned)
+ After
140 participants (actual)
Primary completion date changed
− Before
31 Dec 2026
+ After
12 Feb 2027
A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
NCT06388200 · Ocugen
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting